Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 11, 2001, Pages 5256-5261

  Sarno, Antonella Di ^a   Landi, Maria Luisa ^a   Cappabianca, Paolo ^a   Salle, Francesco Di ^a   Rossi, Francesca W ^a   Pivonello, Rosario ^a   Somma, Carolina Di ^a   Faggiano, Antongiulio ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CORTISONE ACETATE; DESMOPRESSIN; LEVOTHYROXINE; PROLACTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DOSE RESPONSE; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TREATMENT OUTCOME; TUMOR GROWTH;

ADENOMA; ADOLESCENT; ADULT; AGED; BROMOCRIPTINE; DOPAMINE AGONISTS; DRUG RESISTANCE; ERGOLINES; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; HYPOPITUITARISM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES;

EID: 17944368742     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.11.5256     Document Type: Article

References (22)

1. Management of prolactinomas
2. Management of prolactinomas
3. Treatment of prolactinomas
4. Bromocriptine
5. A comparison review of the tolerability profiles of DA agonists in the treatment of hyperprolactinemia and inhibition of lactation
6. Dopamine agonists and pituitary tumor shrinkage
7. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
8. Treatment of macroprolactinoma with cabergoline: A study of 85 patients
9. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
10. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients
11. Late development of resistance to bromocriptine in a patient with macroprolactinoma
12. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine
13. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
14. Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine
15. Prolactinomas and resistance to dopamine-agonists
16. Prolactin-producing pituitary tumor: Resistance to dopamine agonist therapy
17. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinemic disorders: An open, uncontrolled, multicentre study
18. Cabergoline in the long-term therapy of hyperprolactinemic disorders
19. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
20. A first choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
21. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients
22. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases